Excision BioTherapeutics
TypePrivately held company
Industry
FoundedJanuary 2015 (2015-01) in San Francisco, California, United States
Founders
  • Kamel Khalili
  • Daniel Dornbusch
Headquarters
US
Area served
Worldwide
Websiteexcision.bio

Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.

The company has a single, CRISPR–Cas9 based therapy, EBT-101, under invesigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5]

References

  1. ↑ Sheldon, Cormac (30 October 2023). "Armed with gene technologies and CAR-Ts, scientists are attempting to eliminate viruses that escape immune detection and lurk in tissues for years". Nature Medicine. doi:10.1038/s41587-023-02022-0. S2CID 264673741. Retrieved 16 November 2023.
  2. ↑ "The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup says it could be a one-time cure". Business Insider. 27 January 2023. Retrieved 16 November 2023.
  3. ↑ Brzyski, Laura (5 March 2023). "Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial". Philadelphia. Retrieved 16 November 2023.
  4. ↑ Krieger, Lisa (28 October 2023). "CRISPR gene editing could kill HIV. But is it a cure?". The Mercury News. Retrieved 16 November 2023.
  5. ↑ Leuty, Ron (21 July 2023). "S.F. biotech inches closer to potential HIV cure with key move by FDA". San Francisco Business Times. Retrieved 17 November 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.